Skip to main content
SpringerLink
Log in

Tocilizumab: risk of psoriasis?

  • Incidence study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Savage R. Tocilizumab -- Psoriasis and Aggravated psoriasis. WHO Pharmaceuticals Newsletter : 16-21, No. 2, Jun 2014. Available from: URL: http://www.who.int/medicines/publications/PharmNewsNo2_2014.pdf

  2. Roche. Response from Roche (re: Tocilizumab -- Psoriasis and Aggravated psoriasis). WHO Pharmaceuticals Newsletter : 22, No. 2, Jun 2014. Available from: URL: http://www.who.int/medicines/publications/PharmNewsNo2_2014.pdf

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tocilizumab: risk of psoriasis?. Reactions Weekly 1506, 3 (2014). https://doi.org/10.1007/s40278-014-1426-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-1426-0

Search

Navigation